RSNA first-timer biospace med debuts ortho imaging system
Dec. 5 – biospace med was a first-time RSNA exhibitor this year, showcasing its EOS ultra low dose 2D/3D Xray imager at the 93rd scientific assembly and annual meeting of the Radiological Society of North America (RSNA) in Chicago last week.
EOS captures a whole or partial body image in a single scan without the need for digital stitching at a reduced dose. The system allows simultaneous bi-plane image acquisition (frontal and lateral), according to the company.
Information submitted to the FDA in support of biospace med’s marketing application demonstrated up to 10 times reduction in dose when compared with commercially available film systems--without compromising film quality. EOS can also generate a 3D skeletal reconstruction from the two simultaneously acquired planar images. This product also features automatic measurement software designed to calculate a variety of length and angle calculations between individual bones and joints, potentially helping to evaluate global balance and posture.
EOS is based on a patented particle detector technology, for which Georges Charpak, co-founder of the company, received the Nobel Prize in physics. The imager targets the $2 billion orthopedic imaging market, according to Marie Meynadier, president and CEO. The company obtained 510(k) clearance from the FDA in October and the CE Mark last summer. biomed has several installation commitments for first quarter of 2008.
There are large distortion issues when imaging the skeletal spine and lower limbs, Meynadier said. Meanwhile, conditions such as osteoarthritis require relatively high doses of radiation as well as frequent imaging for follow-up. So, the ability to reduce dose is especially important. Orthopedists also often require 3D, weight-bearing images to diagnose and treat their patients.
EOS captures a whole or partial body image in a single scan without the need for digital stitching at a reduced dose. The system allows simultaneous bi-plane image acquisition (frontal and lateral), according to the company.
Information submitted to the FDA in support of biospace med’s marketing application demonstrated up to 10 times reduction in dose when compared with commercially available film systems--without compromising film quality. EOS can also generate a 3D skeletal reconstruction from the two simultaneously acquired planar images. This product also features automatic measurement software designed to calculate a variety of length and angle calculations between individual bones and joints, potentially helping to evaluate global balance and posture.
EOS is based on a patented particle detector technology, for which Georges Charpak, co-founder of the company, received the Nobel Prize in physics. The imager targets the $2 billion orthopedic imaging market, according to Marie Meynadier, president and CEO. The company obtained 510(k) clearance from the FDA in October and the CE Mark last summer. biomed has several installation commitments for first quarter of 2008.
There are large distortion issues when imaging the skeletal spine and lower limbs, Meynadier said. Meanwhile, conditions such as osteoarthritis require relatively high doses of radiation as well as frequent imaging for follow-up. So, the ability to reduce dose is especially important. Orthopedists also often require 3D, weight-bearing images to diagnose and treat their patients.